Naproxen
Granules USA recalls one batch of Naproxen Sodium 220 mg tablets
Hyderabad/UNI: The Granules USA, Inc, a wholly-owned foreign subsidiary of Granules India, has voluntarily recalled one batch of Naproxen Sodium 220 mg tablets at a retail level due to a minor ‘CGMP deviation’
The Hyderabad-based Pharmaceutical company confirmed that one batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled.
Financially, this does not have a material impact on the company, it said.
Granules manufactured and released a batch using Active Pharmaceutical Ingredient (API) from an alternate source prior to the final approval of a filed Prior Approval Supplement.
"We have since received the authorization to use the API for this ANDA. There was absolutely no harm done at a patient-level because the API used in the batch is from an FDA approved source,” said G. N. Prashanth, Senior Vice President & Head Corporate Quality Assurance – Granules India Limited.
Granules has not received any reports of adverse events that have been confirmed to be directly related to this recall as of the date, a senior company official stated.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
